The Antitumor Activity of the Somatostatin Structural Derivative (TT-232) on Different Human Tumor Xenografts

Miguel Tejeda, D. Gaál, K. Barna, O. Csuka, G. Kéri

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

A somatostatin structural derivative (TT-232) has been developed in our laboratory with strong antiproliferative effect but no GH- release inhibitory activity. TT-232 inhibited tyrosine kinase activity of tumor cell lines and this inhibition correlated well with the inhibition of cell proliferation. The antineoplastic activity of TT-232 has been found to be associated with induction of programmed cell death (apoptosis) in tumor cell, resulting in highly selective elimination of neoplastic tissue. The aim of this study was the therapeutic efficacy of TT-232 on different human tumor models: PC-3 prostate carcinoma, MDA-MB-231 (ER-) and MCF-7 (ER+) breast carcinoma, HT-29 colon carcinoma, HT-18 melanoma, HL-60 promyelocytic leukemia. We studied the therapeutic efficacy of the novel somatostatin analog, applying it for 30 days with intermittent injection once daily and for 14 days with s.c. infusion using the Alzet osmotic minipump (model 2002). The antitumor activity of TT-232 was evaluated on the basis of survival time and tumor growth inhibition. The tumor growth inhibitory effect of TT-232 on human tumor xenografts proved to be significant, resulting in 30%-80% decrease in tumor volume and in 20%-60% tumor-free animals. This antitumor efficacy of the novel somatostatin analog was observable in almost all tumors investigated. These data suggest that the novel somatostatin analog (TT-232) is an effective and promising antitumor agent.

Original languageEnglish
Pages (from-to)4061-4066
Number of pages6
JournalAnticancer Research
Volume23
Issue number5 A
Publication statusPublished - Sep 2003

Fingerprint

Somatostatin
Heterografts
Neoplasms
Antineoplastic Agents
Carcinoma
Growth
TT2-32
Tumor Burden
Tumor Cell Line
Protein-Tyrosine Kinases
Prostate
Melanoma
Colon
Leukemia
Cell Death
Cell Proliferation
Apoptosis
Breast Neoplasms
Injections
Survival

Keywords

  • Human tumor xenograft
  • New somatostatin analog
  • TT-232
  • Tumor therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

The Antitumor Activity of the Somatostatin Structural Derivative (TT-232) on Different Human Tumor Xenografts. / Tejeda, Miguel; Gaál, D.; Barna, K.; Csuka, O.; Kéri, G.

In: Anticancer Research, Vol. 23, No. 5 A, 09.2003, p. 4061-4066.

Research output: Contribution to journalArticle

@article{9fbcd35b13a34f72b58e79be4112fcc3,
title = "The Antitumor Activity of the Somatostatin Structural Derivative (TT-232) on Different Human Tumor Xenografts",
abstract = "A somatostatin structural derivative (TT-232) has been developed in our laboratory with strong antiproliferative effect but no GH- release inhibitory activity. TT-232 inhibited tyrosine kinase activity of tumor cell lines and this inhibition correlated well with the inhibition of cell proliferation. The antineoplastic activity of TT-232 has been found to be associated with induction of programmed cell death (apoptosis) in tumor cell, resulting in highly selective elimination of neoplastic tissue. The aim of this study was the therapeutic efficacy of TT-232 on different human tumor models: PC-3 prostate carcinoma, MDA-MB-231 (ER-) and MCF-7 (ER+) breast carcinoma, HT-29 colon carcinoma, HT-18 melanoma, HL-60 promyelocytic leukemia. We studied the therapeutic efficacy of the novel somatostatin analog, applying it for 30 days with intermittent injection once daily and for 14 days with s.c. infusion using the Alzet osmotic minipump (model 2002). The antitumor activity of TT-232 was evaluated on the basis of survival time and tumor growth inhibition. The tumor growth inhibitory effect of TT-232 on human tumor xenografts proved to be significant, resulting in 30{\%}-80{\%} decrease in tumor volume and in 20{\%}-60{\%} tumor-free animals. This antitumor efficacy of the novel somatostatin analog was observable in almost all tumors investigated. These data suggest that the novel somatostatin analog (TT-232) is an effective and promising antitumor agent.",
keywords = "Human tumor xenograft, New somatostatin analog, TT-232, Tumor therapy",
author = "Miguel Tejeda and D. Ga{\'a}l and K. Barna and O. Csuka and G. K{\'e}ri",
year = "2003",
month = "9",
language = "English",
volume = "23",
pages = "4061--4066",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "5 A",

}

TY - JOUR

T1 - The Antitumor Activity of the Somatostatin Structural Derivative (TT-232) on Different Human Tumor Xenografts

AU - Tejeda, Miguel

AU - Gaál, D.

AU - Barna, K.

AU - Csuka, O.

AU - Kéri, G.

PY - 2003/9

Y1 - 2003/9

N2 - A somatostatin structural derivative (TT-232) has been developed in our laboratory with strong antiproliferative effect but no GH- release inhibitory activity. TT-232 inhibited tyrosine kinase activity of tumor cell lines and this inhibition correlated well with the inhibition of cell proliferation. The antineoplastic activity of TT-232 has been found to be associated with induction of programmed cell death (apoptosis) in tumor cell, resulting in highly selective elimination of neoplastic tissue. The aim of this study was the therapeutic efficacy of TT-232 on different human tumor models: PC-3 prostate carcinoma, MDA-MB-231 (ER-) and MCF-7 (ER+) breast carcinoma, HT-29 colon carcinoma, HT-18 melanoma, HL-60 promyelocytic leukemia. We studied the therapeutic efficacy of the novel somatostatin analog, applying it for 30 days with intermittent injection once daily and for 14 days with s.c. infusion using the Alzet osmotic minipump (model 2002). The antitumor activity of TT-232 was evaluated on the basis of survival time and tumor growth inhibition. The tumor growth inhibitory effect of TT-232 on human tumor xenografts proved to be significant, resulting in 30%-80% decrease in tumor volume and in 20%-60% tumor-free animals. This antitumor efficacy of the novel somatostatin analog was observable in almost all tumors investigated. These data suggest that the novel somatostatin analog (TT-232) is an effective and promising antitumor agent.

AB - A somatostatin structural derivative (TT-232) has been developed in our laboratory with strong antiproliferative effect but no GH- release inhibitory activity. TT-232 inhibited tyrosine kinase activity of tumor cell lines and this inhibition correlated well with the inhibition of cell proliferation. The antineoplastic activity of TT-232 has been found to be associated with induction of programmed cell death (apoptosis) in tumor cell, resulting in highly selective elimination of neoplastic tissue. The aim of this study was the therapeutic efficacy of TT-232 on different human tumor models: PC-3 prostate carcinoma, MDA-MB-231 (ER-) and MCF-7 (ER+) breast carcinoma, HT-29 colon carcinoma, HT-18 melanoma, HL-60 promyelocytic leukemia. We studied the therapeutic efficacy of the novel somatostatin analog, applying it for 30 days with intermittent injection once daily and for 14 days with s.c. infusion using the Alzet osmotic minipump (model 2002). The antitumor activity of TT-232 was evaluated on the basis of survival time and tumor growth inhibition. The tumor growth inhibitory effect of TT-232 on human tumor xenografts proved to be significant, resulting in 30%-80% decrease in tumor volume and in 20%-60% tumor-free animals. This antitumor efficacy of the novel somatostatin analog was observable in almost all tumors investigated. These data suggest that the novel somatostatin analog (TT-232) is an effective and promising antitumor agent.

KW - Human tumor xenograft

KW - New somatostatin analog

KW - TT-232

KW - Tumor therapy

UR - http://www.scopus.com/inward/record.url?scp=0344874041&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0344874041&partnerID=8YFLogxK

M3 - Article

C2 - 14666719

AN - SCOPUS:0344874041

VL - 23

SP - 4061

EP - 4066

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 5 A

ER -